review Open AccessTop 1% cited
Targeting cancer with small molecule kinase inhibitors
Nature reviews. Cancer · 2008 · Vol. 9(1) · pp. 28–39
Histone Deacetylase Inhibitors ResearchCancer Mechanisms and TherapyProtein Degradation and InhibitorsKinaseCancerSmall moleculeMechanism (biology)Cancer cellBiologyCancer researchComputational biologyPharmacologyCell biology
MeSH terms
Allosteric RegulationAntineoplastic AgentsBinding SitesHumansModels, MolecularNeoplasm ProteinsNeoplasmsProtein BindingProtein ConformationProtein KinasesSubstrate SpecificityDrug DesignSignal TransductionDrug Delivery SystemsDrug Resistance, Neoplasm
Citations
2,539
FWCI
44.82
field-weighted impact
References
108
Percentile
100%
vs. same field & year
Citations per year
Cited by
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Cancers · 2015 · 340 citations
Polypharmacology: Challenges and Opportunities in Drug Discovery
Journal of Medicinal Chemistry · 2014 · 1,045 citations
Ultradeep Human Phosphoproteome Reveals a Distinct Regulatory Nature of Tyr and Ser/Thr-Based Signaling
Cell Reports · 2014 · 1,015 citations
Targeting the phosphoinositide 3-kinase pathway in cancer
Nature Reviews Drug Discovery · 2009 · 2,742 citations
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
Advanced Drug Delivery Reviews · 2013 · 2,726 citations
Molecular targeted therapy: Treating cancer with specificity
European Journal of Pharmacology · 2018 · 1,045 citations
The cell cycle and cancer
The Journal of Pathology · 2011 · 657 citations
The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
Chemical and Pharmaceutical Bulletin · 2019 · 411 citations
References
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
PLoS Medicine · 2005 · 3,519 citations
Discovery of <i>N</i>-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays
Journal of Medicinal Chemistry · 2004 · 1,285 citations
The Protein Kinase Complement of the Human Genome
Science · 2002 · 8,071 citations
The selectivity of protein kinase inhibitors: a further update
Biochemical Journal · 2007 · 2,500 citations
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition
Nature Structural & Molecular Biology · 2004 · 614 citations
Specificity and mechanism of action of some commonly used protein kinase inhibitors
Biochemical Journal · 2000 · 4,060 citations
A quantitative analysis of kinase inhibitor selectivity
Nature Biotechnology · 2008 · 2,427 citations
A census of human cancer genes
Nature reviews. Cancer · 2004 · 3,334 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.